Compass Biotechnologies Inc invited to speak at The World Generic Medicines Congress Americas 2011
Compass Biotech (OTCBB:COBI) Intraday Stock Chart Today : Tuesday 31 May 2011 Compass Biotechnologies (COBI:OB) is pleased to announce that Dr. Joseph Sinkule President and COO of Compass Biotech has been invited to speak at the fourth annual World Generic Medicines Congress Americas 2011 to be held this fall from November 12 - November 15 at the Westin Grand, Washington D.C.
The Congress is the largest of its kind within the Generics Industry and for the first time this year is expanding to include the World Biosimiliars Summit to help focus on the key challenges facing the commercialization of the soon to be multiple billion dollar biosimiliar US and global markets.
The meeting unites a speaker platform of the highest seniority with all stakeholders in the industry and allows participants to position their products and services in front of decision makers from major Pharma manufacturers and large biotech companies. Dr. Sinkule who will speak on "Strategies and Opportunities for Smaller and Niche Generic Companies"
Dr Sinkule commented "It is indeed an honour and a privilege to be invited to speak at such a timely and prestigious event that will provide excellent exposure for the Company. Further, we feel it speaks to the acceptance of our approach to this increasingly important and growing market sector".
ABOUT COMPASS BIOTECHNOLOGIES INC. (COBI:OB) www.compassbio.net Compass Biotechnologies is a publically-traded specialty biopharmaceutical company (COBI:OB) with headquarters in Edmonton, Alberta. The mission of Compass is to develop generic, biosimiliar and bio-better drug products that can bring revenue generation to the company in a near term fashion. A recent agreement with PanGen to supply protein active pharmaceutical ingredients to facilitate this mission was announced recently. Further Compass under a license from the National Institutes of Health (NIH) has opportunities to develop products from the platform technology available and or sub licensee these opportunities to other interested partners. Compass Biotech also owns a subsidiary company called C-Pharma Inc.
ABOUT C-PHARMA INC. www.c-pharma.net C-Pharma's technology encompasses the use of recombinant DNA technology to manufacture virus like particles (VLPs). These VLPs can be engineered to incorporate various viral and non-viral antigens for use as vaccines against many different types of targets such as Hepatitis C. The recombinant antigens presented in the context of a VLP carrier system are much more immunogenic than the antigen alone, and this carrier is so powerful that the subsequent vaccine may not require the use of immune adjuvants. C-Pharma is using the technology to develop a Hepatitis C vaccine to prevent hepatitis C viral infection of liver hepatocytes. The Company is also pursuing a revenue generation strategy by commercializing generic therapeutic drugs (ribavirin and interferon alpha) for use in the Hepatitis C market.
Forward Looking Statements This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this current report which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainty of financial estimates and projections, the competitive and regulatory environments, stock market conditions, unforeseen technical difficulties and our ongoing ability to operate a business and obtain financing. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that our beliefs, plans, expectations and intentions contained in this current report are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our quarterly reports on Form 10-Q and our other periodic reports filed from time-to-time with the Securities and Exchange Commission pursuant to the Securities Exchange Act. For further information and inquiries: